Safety Study of Intranasal Oxytocin in Frontotemporal Dementia

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2013

Conditions
Frontotemporal Dementia
Interventions
DRUG

oxytocin

Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week

DRUG

Saline Nasal Mist

Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts

Trial Locations (1)

N6A 4V2

Cognitive Neurology and Alzheimer Research Centre, London

All Listed Sponsors
collaborator

Consortium of Canadian Centres for Clinical Cognitive Research

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT01386333 - Safety Study of Intranasal Oxytocin in Frontotemporal Dementia | Biotech Hunter | Biotech Hunter